Growth factors and neuroglobin in astrocyte protection against neurodegeneration and oxidative stress
dc.contributor.author | Cabezas, Ricardo | spa |
dc.contributor.author | Baez-Jurado, Eliana | spa |
dc.contributor.author | Hidalgo-Lanussa, Oscar | spa |
dc.contributor.author | Echeverria, Valentina | spa |
dc.contributor.author | Ashrad, Ghulam Md | spa |
dc.contributor.author | Sahebkar, Amirhossein | spa |
dc.contributor.author | Barreto, George E. | spa |
dc.coverage.campus | CRAI-USTA Bogotá | spa |
dc.date.accessioned | 2019-07-05T21:07:41Z | spa |
dc.date.available | 2019-07-05T21:07:41Z | spa |
dc.date.issued | 2018-07-07 | spa |
dc.description.abstract | Neurodegenerative diseases, such as Parkinson and Alzheimer, are among the main public health issues in the world due to their effects on life quality and high mortality rates. Although neuronal death is the main cause of disruption in the central nervous system (CNS) elicited by these pathologies, other cells such as astrocytes are also affected. There is no treatment for preventing the cellular death during neurodegenerative processes, and current drug therapy is focused on decreasing the associated motor symptoms. For these reasons, it has been necessary to seek new therapeutical procedures, including the use of growth factors to reduce α-synuclein toxicity and misfolding in order to recover neuronal cells and astrocytes. Additionally, it has been shown that some growth factors are able to reduce the overproduction of reactive oxygen species (ROS), which are associated with neuronal death through activation of antioxidative enzymes such as catalase, superoxide dismutase, glutathione peroxidase, and neuroglobin. In the present review, we discuss the use of growth factors such as PDGF-BB, VEGF, BDNF, and the antioxidative enzyme neuroglobin in the protection of astrocytes and neurons during the development of neurodegenerative diseases. | spa |
dc.description.domain | http://unidadinvestigacion.usta.edu.co | spa |
dc.format.mimetype | application/pdf | spa |
dc.identifier.doi | https://doi.org/10.1007/s12035-018-1203-9 | spa |
dc.identifier.uri | http://hdl.handle.net/11634/17479 | |
dc.relation.references | Liu B, Gao HM, Hong JS (2003) Parkinson’s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 111(8):1065–1073 | spa |
dc.relation.references | Dos Santos AB, Barreto GE, Kohlmeier KA (2014) Treatment of sleeping disorders should be considered in clinical management of Parkinson’s disease. Front Aging Neurosci 6:273 | spa |
dc.relation.references | Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord 26(1):6–17 | spa |
dc.relation.references | Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278(10):8516–8525 | spa |
dc.relation.references | Nutt JG,Wooten GF (2005) Clinical practice. diagnosis and initial management of Parkinson’s disease. N Engl JMed 353(10):1021– 1027 | spa |
dc.relation.references | Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS et al (2011) Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 68(2):165 | spa |
dc.relation.references | Hauser RA,McDermott MP,Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63(12):1756–1760 | spa |
dc.relation.references | Post B, Muslimovic D, van Geloven N, Speelman JD, Schmand B, de Haan RJ, C.A.-s. group (2011) Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson’s disease. Mov Disord 26(3):449–456 | spa |
dc.relation.references | Avila-Rodriguez M, Garcia-Segura LM, Hidalgo-Lanussa O, Baez E, Gonzalez J, Barreto GE (2016) Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression. Mol Cell Endocrinol 433:35–46 | spa |
dc.relation.references | Baez-Jurado E, Vega GG, Aliev G, Tarasov VV, Esquinas P, EcheverriaV, Barreto GE (2018) Blockade of neuroglobin reduces protection of conditioned medium from human mesenchymal stemcells in human astrocyte model (T98G) under a scratch assay. Mol Neurobiol 55(3):2285–2300 | spa |
dc.relation.references | Correia AS, Anisimov SV, Li JY, Brundin P (2005) Stem cellbased therapy for Parkinson’s disease. Ann Med 37(7):487–498 | spa |
dc.relation.references | Paul G, Zachrisson O, Varrone A, Almqvist P, Jerling M, Lind G, Rehncrona S, Linderoth B et al (2015) Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients. J Clin Invest 125(3):1339–1346 | spa |
dc.relation.references | Falk T, Zhang S, Sherman SJ (2009) Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson’s disease. Mol Neurodegener 4:49 | spa |
dc.relation.references | Henriques A, Pitzer C, Schneider A (2010) Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci 4:32 | spa |
dc.relation.references | Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N YAcad Sci 1144:97–112 | spa |
dc.relation.references | Ramaswamy S, Kordower JH (2009) Are growth factors the answer? Parkinsonism Relat Disord 15(Suppl 3):S176–S180 | spa |
dc.relation.references | Zachrisson O, Zhao M, Andersson A, Dannaeus K, Haggblad J, Isacson R, Nielsen E, Patrone C et al (2011) Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson’s disease. J Parkinson’s Dis 1(1):49–63 | spa |
dc.relation.references | Weissmiller AM, Wu C (2012) Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener 1(1):14 | spa |
dc.relation.references | Iihara K, Hashimoto N, Tsukahara T, Sakata M, Yanamoto H, Taniguchi T (1997) Platelet-derived growth factor-BB, but not - AA, prevents delayed neuronal death after forebrain ischemia in rats. J Cereb Blood Flow Metab 17(10):1097–1106 | spa |
dc.relation.references | Peng F, Yao H, Akturk HK, Buch S (2012) Platelet-derived growth factor CC-mediated neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta. PLoS One 7(10):e47572 | spa |
dc.rights | Atribución-NoComercial-CompartirIgual 2.5 Colombia | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/2.5/co/ | * |
dc.subject.keyword | Neuroglobin | spa |
dc.subject.keyword | Astrocyte | spa |
dc.subject.keyword | Oxidative stress | spa |
dc.subject.keyword | Neurodegeneration | spa |
dc.title | Growth factors and neuroglobin in astrocyte protection against neurodegeneration and oxidative stress | spa |
dc.type.category | Generación de Nuevo Conocimiento: Artículos publicados en revistas especializadas - Electrónicos | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- Growth factors and neuroglobin in astrocyte protection against neurodegeneration and oxidative stress.pdf
- Tamaño:
- 1.63 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Artículo SCOPUS
Bloque de licencias
1 - 1 de 1

- Nombre:
- license.txt
- Tamaño:
- 807 B
- Formato:
- Item-specific license agreed upon to submission
- Descripción: